MMMarcelo Jenné Mimica

Marcelo Jenné Mimica

*This is an algorithmically generated author record based on publicly available information.

Marcelo Jenné Mimica has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health care costs during the first 20 years of life in infants with hypoxic-ischemic encephalopathy in Brazil: estimated economic benefits generated by the use of therapeutic hypothermia and brain monitoring / Custos em saúde durante os primeiros 20 anos de vida de lactentes com encefalopatia hipóxico-isquêmica no Brasil: benefícios econômicos estimados gerados pelo uso de hipotermia terapêutica e monitoramento cerebral

    by Gabriel Fernando Todeschi Variane, Alexandre Netto, Daniela Pereira Rodrigues, Danieli Mayumi Kimura Leandro, Carolina Nunes de França, Nathalie Sales Llaguno, Maurício Magalhães, Rafaela Fabri Rodrigues Pietrobom, Teresa Maria Lopes de Oliveira Uras Belém, Marcelo Jenné Mimica

    Background: Hypoxic-ischaemic encephalopathy (HIE) is a leading cause of long-term disability. Infants with HIE may require specific lifelong care, representing a devastating social and economic impact. Therapeutic hypothermia (TH) has been proven to be a safe and effective treatment; however, its potential economic impact associated with continuous electroencephalographic monitoring is still unknown in Brazil. This study aimed to evaluate the potential economic benefits provided by TH and continuous electroencephalographic monitoring in the first 20 years of life in infants with HIE in Brazil. Methods: A resource utilization questionnaire about healthcare of infants with HIE was answered by 57 pediatricians and neonatologists in all five regions of Brazil. This data was used to calculate an annual weighted average of patient management costs according to the presence or degree of disability, considering only directly related health costs. A mathematical calculation was performed considering local incidence of HIE and the number of live births per year. Rates of death and survival for different levels of disability and the effect of TH on these outcomes were estimated from the two most relevant randomized controlled trials on TH. Results: There was an approximately 26-fold increase in spending when the severe disability group was compared to the no disability group (p-value<0.0001, ANOVA-Bonferroni). The estimated total cost of patients with no disability, mild, moderate, and severe disability is US$ 6,808.53, US$ 32,208.43, US$ 105,791.78 and US$ 175,698.58, respectively, and the estimated costs related to the use of TH and neuromonitoring were estimated in US$ 2,824.00. Considering a weighted average between TOBY trial and NICHD trial, it is estimated annual savings of US$ 39,700,000-79,401,000. Conclusions: This study estimated a significant increase in the costs associated with the degree of disability and a positive impact of TH throughout the first 20 years of life. Keywords: Children with disability, Health care costs, Hypoxic-ischemic encephalopathy, Neonatal intensive care, Therapeutic hypothermia Resumo Introdução: A encefalopatia hipóxico-isquêmica (EHI) é uma das principais causas de deficiência incapacitante a longo prazo. Recém-nascidos (RN) com EHI podem necessitar de cuidados específicos ao longo da vida, representando um impacto social e econômico devastador. A hipotermia terapêutica (HT) é comprovadamente um tratamento seguro e eficaz; entretanto, seu potencial impacto econômico associado ao monitoramento eletroencefalográfico contínuo ainda é desconhecido no Brasil. Este estudo tem como objetivo avaliar os potenciais benefícios econômicos proporcionados pela HT e pela monitorização eletroencefalográfica contínua nos primeiros 20 anos de vida em lactentes com EHI no Brasil. Métodos: Um questionário de utilização de recursos sobre cuidados de saúde de crianças com EHI foi respondido por 57 pediatras e neonatologistas das cinco regiões do Brasil. Esses dados foram usados para calcular uma média anual ponderada dos custos de cuidados de saúde destes pacientes de acordo com a presença ou grau de incapacidade, considerando apenas custos de saúde diretos. Um cálculo matemático foi realizado considerando a incidência local de EHI e o número de nascidos vivos por ano. As taxas de mortalidade e de sobrevivência para diferentes níveis de incapacidade e o efeito da HT nestes resultados foram estimados a partir dos dois ensaios clínicos randomizados e controlados mais relevantes sobre a HT. Resultados: Houve um aumento de aproximadamente 26 vezes nos gastos quando o grupo com deficiência grave foi comparado ao grupo sem deficiência (p-valor<0,0001, ANOVA-Bonferroni). O custo total estimado para os pacientes sem incapacidade, com incapacidade leve, moderada e grave é de US$ 6.808,53, US$ 32.208,43, US$ 105.791,78 e US$ 175.698,58, respetivamente, e os custos estimados relacionados ao uso da HT e da neuromonitoramento foram estimados em US$ 2.824,00. Considerando uma média ponderada entre o estudo TOBY e o estudo NICHD, estima-se uma economia anual de US$ 39.700.000-79.401.000. Conclusões: Este estudo estimou um aumento significativo dos custos associados ao grau de incapacidade e um impacto positivo da HT ao longo dos primeiros 20 anos de vida. Palavras-chave: Crianças com deficiência, Custos de cuidados de saúde, Encefalopatia hipóxica-isquêmica, Terapia intensiva neonatal, Hipotermia induzida


  • Open Access

    Mobile phones of anesthesiologists as reservoirs of nosocomial bacteria in a quaternary teaching hospital: an observational study

    by Guilherme Haelvoet Correa, Carla de Souza Formigoni, Suzethe Matiko Sasagawa, Mariana Volpe Arnoni, Lígia Andrade da Silva Telles Mathias, Marcelo Jennè Mimica


  • Efficacy of an adjuvant Lactobacillus rhamnosus formula in improving skin lesions as assessed by PASI in patients with plaque psoriasis from a university-affiliated, tertiary-referral hospital in São Paulo (Brazil): a parallel, double-blind, randomized clinical trial

    by Enrico Stefano Suriano, Marília Diogo Moço Souza, Clarice Marie Kobata, Felipe Henrique Yazawa Santos, Marcelo Jenné Mimica

    Psoriasis is an inflammatory disease of the skin, characterized by erythematous plaques. It is rather common, affecting 2–4% of the population in western countries. Psoriasis’ etiology encompasses both genetic and environmental factors. Evidence suggests that the latter reflect the importance of changes in the microbiome for developing the disease. Thus, it is hypothesized that gut microbiome manipulation may arise as a way of treating psoriasis. However, few trials assessed the use of probiotics in psoriasis, although promising results were detected in small studies. Our objective was to assess the efficacy of adjuvant probiotics (Lactobacillus rhamnosus) in treating plaque psoriasis patients. This was a randomized, parallel, placebo-controlled, double-blind trial with two arms: experimental (n = 50) and control (n = 53). Inclusion of subjects and data gathering lasted from November 2020 to August 2021. Subjects were consecutive plaque psoriasis patients under regular follow-up in the Dermatology unit of a university-affiliated, tertiary-referral hospital in São Paulo (Brazil). Eligibility criteria included being over 18 years old, having plaque psoriasis and not having other skin diseases, neoplasms nor systemic inflammatory diseases. Subjects received standard-of-care plus probiotics (Lactobacillus rhamnosus formula). Controls received standard-of-care plus placebo. Primary outcome was skin lesion improvement as assessed by psoriasis area of severity index (PASI) at six months. Secondary outcome was quality-of-life as assessed by dermatology life quality index (DLQI) at six months. Regarding within-group analyses, changes in both PASI and DLQI were non-significant for the experimental group (mean PASI decreased by 1.58, p = 0.105, and mean DLQI increased by 0.05, p = 0.873) and significant for controls (mean PASI decreased by 1.90, p = 0.019, and mean DLQI decreased by 3.33, p = 0.031). Between-group analyses returned non-significant results (p = 0.620). Our findings do not support the hypothesis that gut microbiome modulation via ingestion of Lactobacillus rhamnosus produces clinical improvement in psoriasis patients. Further research is encouraged. Trial registration: Retrospectively registered at the Brazilian Clinical Trials Registry (RBR-8js7t83) on 08/02/2022.


  • Open Access

    Probiotic therapy outcomes in body composition of children and adolescent with obesity, a nonrandomized controlled trial

    by Thaís Léo Pacheco Marcelo, Caroline Rosa Pellicciari, Thiago Olivetti Artioli, Dânae Braga Diamante Leiderman, Ana Lúcia Torloni Gradinar, Marcelo Mimica, Cristiane Kochi

    Objective: The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity. Subjects and methods: This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional [...] ABSTRACT Objective: The objective of this study was to evaluate the impact of probiotic supplementation therapy on anthropometric values and body composition of children and adolescent with obesity. Subjects and methods: This is a nonrandomized controlled, prospective, double-blind interventional clinical trial with primary data analysis. The sample comprised 44 pubertal children and adolescent (8-17 years old) with obesity. The patients were allocated to probiotic (Lactobacillus rhamnosus) or placebo group, with matching of gender and chronological age. Both groups received nutritional


  • Open Access

    First report of two consecutive respiratory syncytial virus outbreaks by the novel genotypes ON‐1 and NA‐2 in a neonatal intensive care unit

    by Daniella Gregoria Bomfim Prado da Silva, Flávia Jacqueline Almeida, Mariana Volpe Arnoni, Marco Aurélio Palazzi Sáfadi, Marcelo Jenne Mimica, Daniel Jarovsky, Gabriela Pereira de Almeida Rossetti, Mauricio Magalhães, Danielle Bruna Leal de Oliveira, Luciano Matsumiya Thomazelli, et al.

  • Open Access

    Osteoarticular infections in pediatrics

    by Paula Andrade Alvares, Marcelo Jenné Mimica


  • Open Access

    First report of two consecutive respiratory syncytial virus outbreaks by the novel genotypes ON-1 and NA-2 in a neonatal intensive care unit

    by Daniella Gregoria Bomfim Prado da Silva, Flávia Jacqueline Almeida, Mariana Volpe Arnoni, Marco Aurélio Palazzi Sáfadi, Marcelo Jenne Mimica, Daniel Jarovsky, Gabriela Pereira de Almeida Rossetti, Mauricio Magalhães, Danielle Bruna Leal de Oliveira, Luciano Matsumiya Thomazelli, et al.


  • Open Access

    Osteoarticular infections in pediatrics

    by Paula Andrade Alvares, Marcelo Jenné Mimica


  • Open Access

    Evaluating vancomycin susceptibility in Staphylococcus aureus

    by Marcelo J Mimica, Alessandra Navarini

    Evaluating vancomycin susceptibility in Staphylococcus aureus Marcelo J Mimica, Alessandra Navarini Department of Pathology, Division of Microbiology, Santa Casa de São Paulo School of Medicine, São Paulo, BrazilWe read the report by Phillips et al1 with great interest and would like to discuss it in comparison with our previous published data on the subject.2,3We have also studied a number of Staphylococcus aureus clinical isolates (n=125), comparing different vancomycin susceptibility tests, including microdilution, Etest® (bio-Mérieux, Marcy-l’Étoile, France), and brain heart infusion vancomycin screening plates. We found only one isolate with reduced susceptibility with a minimum inhibitory concentration (MIC) =4 mg/L when tested with Etest and 2 mg/L when tested with microdilution.2,3 Our results showed a tendency of higher lethality when higher MICs were present, even within the susceptible range,3 as some previous studies have shown.4,5Concordant to Phillips et al1 and other authors,6,7 we also reported a poor correlation between different tests. Comparing Etest and microdilution (approximating an Etest MIC value between two twofold dilutions up to the highest value), 58% of the isolates had similar MICs, whereas 38% had an MIC by Etest one dilution higher than microdilution. One isolate had an Etest MIC twofold higher and four isolates an Etest MIC onefold lower than microdilution.2However, in our study, a brain heart infusion screening plate with 2.0 mg/L of vancomycin showed a sensitivity of 100% to detect isolates with an MIC ≥2.0 by Etest and 91% to detect an MIC ≥2.0 by microdilution, making this test an interestingoption for initial screening of S. aureus isolates for reduced vancomycin susceptibility. Specificities were 63% and 38%, respectively, which would still make necessary the further testing with an MIC method, but in a much smaller number of isolates.2 This approach would be suitable for a large number of laboratories throughout the world where the routine MIC testing of all S. aureus isolates is not feasible.View original paper by Phillips et al.


  • Mupirocin susceptibility in Staphylococcus aureus nasal and oropharyngeal isolates from Brazilian children

    by Maria Fernanda B. Pereira, Eitan N. Berezin, Rozane L. Carvalho, Daniel K. Scheffer, Marcelo J. Mimica

    Mupirocin is a topical antimicrobial agent and part of most Staphylococcus aureus decolonization regimens. Thus, knowing the mupirocin susceptibility profile of colonizing S. aureus is paramount for the proper use of this agent. We evaluated S. aureus isolates from 128 colonized children, using disc diffusion (with 5 mcg and 200 mcg discs) and Etest. None were low-level or high-level mupirocin-resistant. Since mupirocin will be increasingly needed for the control of S. aureus infection, continuous monitoring of its susceptibility status is necessary.